InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
4
Disclosed sells
0
T+90 hit rate
43%
T+90 mean return
-0.8%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by FONTEYNE PAUL R., Director. Officer active across 5 companies, notably Apellis Pharmaceuticals, Inc.. Aggregated, 14 disclosures have been published. Split: 4 buys · 0 sell. Total volume traded: €331k. Activity tracked since 10 August 2021. The latest transaction was disclosed on 1 January 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
30,666 sharesCommon StockSEC:0001193125-26-224618
30,666 sharesCommon StockSEC:0001193125-26-224618:0
6,267 shares0Common StockSEC:0001127602-25-000425:0
3,341 shares0Common StockSEC:0001127602-24-000120:0
3,867 shares0Common StockSEC:0000899243-23-000668:0
13,275 shares0Common StockSEC:0001752836-22-000143:0
8,275 shares0Common StockSEC:0001752836-22-000098:0
53,832 sharesCommon StockSEC:0001104659-22-057532:0
3,947 shares@ US$19.00100.0% of flowCommon StockSEC:0000899243-22-001527
Ideal exit: 3 Oct 2022 (T+270)
3,947 shares@ US$19.000.0045% mcap50.0% of flowCommon StockSEC:0000899243-22-001527:0
Ideal exit: 3 Oct 2022 (T+270)
4,230 shares0Common StockSEC:0001127602-22-000726:0
4,230 shares0Common StockSEC:0001127602-22-000726
5,000 shares@ US$23.2450.0% of flowCommon StockSEC:0001752836-21-000236:0
Ideal exit: 7 May 2022 (T+270)
5,000 shares@ US$23.2450.0% of flowCommon StockSEC:0001752836-21-000236
Ideal exit: 7 May 2022 (T+270)
14 of 14 declarations
About FONTEYNE PAUL R.
Paul R. Fonteyne is a Director of Apellis Pharmaceuticals, Inc. and COVETRUS, INC. He plays a key role in the governance of these companies and in strategic decision-making.
